Aspira Women’s Health initiated with a Buy at Alliance Global Partners

Alliance Global Partners initiated coverage of Aspira Women’s Health with a Buy rating and $5.60 price target. The company’s portfolio of tests focused on serious gynecological diseases exhibits the ideal “reimbursement recipe,” the analyst tells investors in a research note. The firm believes Aspira shares appear overlooked, “offering investors significant opportunity.”